How FAI creates focal cartilage defects in the hip

In cam-type femoroacetabular impingement, the femoral head is not a true sphere — it carries a flattened or enlarged bump at the head-neck junction. Every time the hip moves into deep flexion or internal rotation, that irregular surface jams against the anterosuperior rim of the acetabulum. Repeated contact drives shear stress directly into the articular cartilage at that contact zone, and over time the cartilage is levered away from the underlying bone, creating a full-thickness defect at a predictable location.

Pincer-type FAI works differently: excessive acetabular coverage over-constrains the femoral head, crushing the labral-chondral junction with each movement cycle. The damage pattern is still focal — concentrated at the rim — rather than spread evenly across the joint surface.

This distinction matters more than it may initially appear. Both cam and pincer produce a spatially constrained lesion: a discrete hole or flap sitting within cartilage that is otherwise intact. That is the opposite of generalised hip osteoarthritis, where surface loss is diffuse and map-like across the whole joint. A focal defect has healthy borders, a defined size, and an identifiable mechanical cause — all prerequisites for targeted cartilage repair to be biologically plausible, and together they define which patients are genuinely eligible.

Left untreated, the mechanical load that created the defect continues to act on it. Molecular studies show that cartilage from FAI hips displays progressive MMP-13-driven catabolism and autophagy dysregulation — pathways that widen existing damage even after the initial injury has occurred, reinforcing the case for early intervention.

Why hip cartilage cannot repair itself without help

Articular cartilage — the smooth, pearlescent lining of the femoral head and acetabulum — has no direct blood supply. Unlike bone or muscle, it cannot call on the vascular healing response that closes a fracture or knits a torn tendon. The chondrocytes embedded within it are largely dormant in adults, and when a full-thickness defect opens in the joint surface, those cells have no meaningful capacity to migrate across and fill the gap.

What happens instead is less forgiving. The exposed subchondral bone beneath the defect is placed under direct mechanical load with every step, sustaining further damage and releasing inflammatory signals that accelerate the breakdown of surrounding cartilage. Time does not improve the situation; it tends to enlarge it.

ChondroFiller injection is designed specifically to address this biological shortfall. The injectable collagen scaffold acts as a structural template, filling the defect and creating the conditions for the patient's own progenitor cells to migrate in — a process the body cannot initiate unaided. This is what separates it from analgesic or anti-inflammatory injections: rather than managing pain signals, it targets the underlying structural deficit in the hip joint.

How ChondroFiller injection works in the hip joint

ChondroFiller injection is built around a simple biological principle: rather than transplanting cells, it provides the structure those cells need to arrive on their own. The material is an acellular, acid-extracted Type I collagen hydrogel — it contains no donor cells and no externally added growth factors. Injected into the cartilage defect, it self-polymerises within three to five minutes, forming a firm, three-dimensional scaffold that conforms to the shape of the lesion. Once stable, this collagen matrix acts as both a structural template and a homing signal: the patient's own progenitor cells migrate in from surrounding tissue and synovial fluid, a process known as matrix-induced chondrogenesis.

The current service pathway delivers ChondroFiller as an outpatient injection under local anaesthesia, guided in real time by ultrasound or fluoroscopy — no operating theatre, no general anaesthetic, and no incisions. In the hip, image guidance is not an optional refinement. Because the joint lies four to eight centimetres beneath overlying soft tissue, landmark injection reaches the joint cavity in only around 72% of attempts (95% CI 56–85%); with ultrasound or fluoroscopic guidance, accurate intra-articular placement approaches 100% (95% CI 98–100%). The anatomy of the anterior hip reinforces this further: the femoral artery sits approximately 1.9 cm medial to the anterior capsule, the femoral vein 1.7 cm medial, and the femoral nerve 2.3 cm lateral. Image-guided placement keeps the needle precisely where it needs to be and away from the structures that surround it.

Which patients are suitable candidates

Selecting the right candidates matters as much as the treatment itself. ChondroFiller injection is designed for focal, full-depth cartilage damage — a discrete defect on the femoral head or acetabulum confirmed on MRI, typically graded III or IV and measuring between 1 and 6 cm² in area.

A suitable candidate also has a mechanically stable hip with no widespread joint-space narrowing. Tönnis grading — a radiographic measure of osteoarthritis severity on a 0–3 scale — provides a useful benchmark here: patients at grade 0 or 1 (no or only minimal change) are the most appropriate. Published data from the 26-patient FAI cohort confirm this directly: patients with Tönnis grade 2 or 3 at the time of treatment had poor outcomes regardless of how the cartilage defect was managed.

One aspect requiring an explicit management plan is the bony impingement that created the defect in the first place. A ChondroFiller injection fills the cartilage hole but does not reshape the cam or pincer abnormality responsible for it; without correcting that morphology, the repaired surface faces the same mechanical overload that caused the original damage. Both problems need to be included in the overall treatment strategy.

Concurrent labral tears warrant individual clinical assessment — significant labral instability may need to be managed before or alongside cartilage repair. Patients with diffuse joint-space loss or advanced osteoarthritis are unlikely to be suitable candidates for this pathway; at that stage, a conversation about hip replacement is the more appropriate next step.

What the clinical evidence shows for hip outcomes

Eighty-one per cent of traceable patients in the primary FAI cohort achieved good or excellent outcomes at three to five years — a mean Harris Hip Score improvement of approximately +33 points. MRI MOCART regeneration scores of 70 to 87 at follow-up confirm scaffold integration and cartilage fill rather than surface-only coverage.

The context behind those figures matters. The cohort numbers 26 patients, carries manufacturer association, and has no randomised control group; large independent RCTs specifically in the hip are currently absent. The 2021 study itself flags long-term outcome data as an outstanding gap. Clinical data to date support reasonable optimism for appropriately selected patients — not certainty across all presentations.

Further evidence adds texture without replacing that core limitation. A 2025 case report of a 32-year-old male with a 15 mm × 5 mm superoanterior femoral head defect — treated with ChondroFiller without microfracture — achieved complete pain relief, full hip range of motion, and normal gait post-operatively, preserving the subchondral bone intact. Across the broader ChondroFiller evidence base covering multiple joints, the reported complaint rate is approximately 0.06%, indicating a favourable safety profile. A multicentre knee RCT demonstrates that the collagen scaffold supports measurable functional gains — useful corroboration of the mechanism, though not a substitute for hip-specific controlled trial data.

Over 19,000 cases have been performed globally, offering a meaningful measure of procedural experience.

The procedure, recovery, and ongoing care pathway

Protected weight-bearing for four to six weeks is the most important practical requirement in the recovery period. Biomechanical in-vitro research confirms that the forming collagen scaffold has limited initial stability — early full loading risks disrupting the matrix before it has integrated with surrounding tissue. A walking aid during this window is mechanically necessary rather than precautionary, and following this guidance directly affects whether the scaffold matures as intended.

Once protected loading ends, a graduated return to activity follows under physiotherapy supervision. Follow-up MRI at approximately six to twelve months allows MOCART scoring — a validated index of scaffold integration and cartilage fill — to confirm whether repair tissue has developed as expected. Published series report MOCART scores of 70 to 87 in patients achieving satisfactory integration.

ChondroFiller injection is one component of a managed hip preservation journey rather than a single-event fix. Physiotherapy, structured activity modification, and load management continue through recovery and beyond, addressing the hip mechanics and muscle balance that determine long-term function. Monitoring over time matters because stable outcomes depend on maintaining a favourable joint environment, not only filling the defect.

For patients in Lincolnshire and the surrounding region at this stage of a treatment decision, Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment — with clinics in Sleaford and Grantham offering a local starting point for establishing whether ChondroFiller injection forms an appropriate part of an individual's hip preservation plan.

1. [1] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176
2. [2] Influence of Cartilage Defects and a Collagen Gel on Integrity of Corresponding Intact Cartilage — Biomechanical In-Vitro Study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
3. [3] Multi-centre RCT Comparing Arthroscopic Hip Surgery to Physiotherapy for FAI — Australian FASHIoN Trial. (2021). https://doi.org/10.1186/s12891-021-04576-z https://doi.org/10.1186/s12891-021-04576-z